Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
Current price $21.18
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Oct 13, 26 |
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Sep 30, 26 | Patience John | director, other: Chairman | M-Exempt | 1,360 | — |
| TD Cowen |
| maintain |
| Buy |
| Buy |
| Sep 25, 26 | HC Wainwright & Co. | maintain | Buy | Buy |
| Aug 10, 26 | Canaccord Genuity | maintain | Buy | Buy |
| Aug 6, 26 | HC Wainwright & Co. | maintain | Buy | Buy |
| Jun 18, 26 | Canaccord Genuity | maintain | Buy | Buy |
| May 5, 26 | Canaccord Genuity | maintain | Buy | Buy |
| Feb 27, 26 | William Blair | upgrade | Market Perform | Outperform |
| Feb 17, 26 | Canaccord Genuity | maintain | Buy | Buy |
| Sep 19, 25 | Canaccord Genuity | maintain | Buy | Buy |
| Sep 30, 26 |
| Patience John |
| director, other: Chairman |
| M-Exempt |
| 1,360 |
| — |
| Aug 12, 26 | Schuler Jack W | 10 percent owner, other: Emeritus Director | P-Purchase | 15,000 @ $24.47 | $367.0K |
| Aug 11, 26 | Schuler Jack W | 10 percent owner, other: Emeritus Director | P-Purchase | 13,700 @ $24.01 | $328.9K |
| Aug 10, 26 | Schuler Jack W | 10 percent owner, other: Emeritus Director | P-Purchase | 13,900 @ $24.25 | $337.0K |
| Jun 30, 26 | Patience John | director, other: Chairman | M-Exempt | 1,361 | — |
| Jun 30, 26 | Patience John | director, other: Chairman | M-Exempt | 1,361 | — |
| Mar 31, 26 | Patience John | director, other: Chairman | M-Exempt | 1,361 | — |
FY2025 · 10-K disclosure
Stock news · updated daily
LOUISVILLE, Colo., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that it will release financial results for the third quarter ended September 30, 2026 after the close of trading on Thursday, November 5. Biodesix management will host a conference call and webcast to discuss its financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day.
New CHEST framework developed by a renowned multidisciplinary panel with expertise in building and managing lung nodule programs across diverse clinical practices New CHEST framework developed by a renowned multidisciplinary panel with expertise in building and managing lung nodule programs across diverse clinical practices
Partnership with Vanderbilt University and Vanderbilt Health accelerates development of the first radiomics-based test for lung nodule risk assessment Partnership with Vanderbilt University and Vanderbilt Health accelerates development of the first radiomics-based test for lung nodule risk assessment
New sponsored and independent research evaluates clinical utility, patient follow-up, and diagnostic test sequencing New sponsored and independent research evaluates clinical utility, patient follow-up, and diagnostic test sequencing
BDSX advances two blood-based MRD programs with Bio-Rad and Thermo Fisher to broaden access to cancer monitoring.
Biodesix-led tumor-informed and tumor-naïve programs draw on the company's bioinformatics and diagnostics test development expertise Biodesix-led tumor-informed and tumor-naïve programs draw on the company's bioinformatics and diagnostics test development expertise
Industry-leading QA/RA excellence accelerates patient access to Biodesix Lab testing, which helps improve overall outcomes for patients with lung nodules Industry-leading QA/RA excellence accelerates patient access to Biodesix Lab testing, which helps improve overall outcomes for patients with lung nodules
Biodesix, Inc. (NASDAQ: BDSX - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the five analysts that are presently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, three have issued a buy recommendation and one has given a strong buy recommendation to the
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Aug 5, 2026 | -0.90 | -0.71 | Beat 21.3% | $26.86M |
| May 4, 2026 | -1.26 | -0.81 | Beat 35.7% | $25.55M |
| Feb 26, 2026 | -1.05 | -0.49 | Beat 53.3% | $28.75M |
| Nov 3, 2025 | -1.60 | -1.16 | Beat 27.5% | $21.77M |
| Aug 7, 2025 | -1.40 | -1.60 | Miss -14.3% | $20.02M |
| May 13, 2025 | -1.40 | -1.60 | Miss -14.6% | $17.96M |
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| 4 | Oct 2, 2026 | 2026-10-02 16:13:27 | View |
| 4 | Aug 13, 2026 | 2026-08-13 17:22:51 | View |
| 4 | Aug 12, 2026 | 2026-08-12 17:55:16 | View |
| 10-Q | Aug 5, 2026 | 2026-08-05 16:05:51 | View |
| 8-K | Aug 5, 2026 | 2026-08-05 16:02:14 | View |
| 4 | Jul 2, 2026 | 2026-07-02 16:27:45 | View |
| SC 13G | Jun 18, 2026 | 2026-06-18 17:00:53 | View |
| EFFECT | May 29, 2026 | 2026-06-01 00:15:30 | View |
| 424B3 | Jun 1, 2026 | 2026-05-29 17:31:16 | View |
| S-3 | May 21, 2026 | 2026-05-21 16:39:10 | View |
Proxy statement (DEF 14A) disclosures
TTM vs. 5-year historical average (annual ratios)
| Metric | BDSX | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | -6.7x | -2.8x · sector 20.7x | Discount |
| Forward P/E (FY26E) | -7.9x | EPS est. -2.67 | Elevated |
| Price / Book | 23.8x | 6.7x | Elevated |
| Price / Sales | 1.7x | 2.3x | Discount |
| EV / EBITDA | -15.0x | -4.6x | Elevated |
| Return on equity | -788.2% | — | Weak |
| Gross margin | 82.5% | 67.9% | Above hist. |
| Debt / Equity | 7.85 | -2.26 | Levered |
| Piotroski / Altman Z | 4/9 | Z -5.43 | Distress |
Discounted cash flow model
1255 daily bars · split adjusted
Daily · Wilder smoothing
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 30.63 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 12.29 | Oscillator | Buy |
| Williams %R (14) | -99.21 | Oscillator | Buy |
| MACD (12, 26, 9) | -1.19 (Hist -0.46) | Oscillator | Strong Sell |
| Average Directional Index (14) | 21.16 (+DI 12.2 / -DI 25.8) | Trend | Sell |
| EMA 20 | 25.13 | MA | Strong Sell |
| SMA 20 | 25.95 | MA | Strong Sell |
| EMA 50 | 25.38 | MA | Strong Sell |
| SMA 50 | 26.56 | MA | Strong Sell |
| SMA 200 | 18.29 | MA | Strong Buy |